United Kingdom (UK) Geographic Atrophy Market (2025-2031) | Size & Revenue, Companies, Growth, Trends, Analysis, Forecast, Segmentation, Industry, Competitive Landscape, Outlook, Value, Share

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United Kingdom (UK) Country Macro Economic Indicators

3.2 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, 2021 & 2031F

3.3 United Kingdom (UK) Geographic Atrophy Market - Industry Life Cycle

3.4 United Kingdom (UK) Geographic Atrophy Market - Porter's Five Forces

3.5 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume Share, By Age Group, 2021 & 2031F

3.6 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F

3.7 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume Share, By Therapeutic Agents Clinical Phase, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of age-related macular degeneration (AMD) in the UK

4.2.2 Growing aging population in the UK

4.2.3 Technological advancements in diagnostic tools and treatment options for geographic atrophy

4.3 Market Restraints

4.3.1 High cost of treatment and limited reimbursement policies

4.3.2 Regulatory challenges in approving new therapies for geographic atrophy

4.3.3 Lack of awareness about geographic atrophy among patients and healthcare providers

6.1 United Kingdom (UK) Geographic Atrophy Market, By Age Group

6.1.1 Overview and Analysis

6.1.2 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, By Age Group, 2021- 2031F

6.1.3 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, By Above 60 Years, 2021- 2031F

6.1.4 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, By Above 75 Years, 2021- 2031F

6.2 United Kingdom (UK) Geographic Atrophy Market, By Diagnosis

6.2.1 Overview and Analysis

6.2.2 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, By Fundus Autofluorescence (FAF), 2021- 2031F

6.2.3 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, By Optical Coherence Tomography Angiography (OCT-A), 2021- 2031F

6.2.4 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, By Multifocal Electroretinography (MfERG), 2021- 2031F

6.3 United Kingdom (UK) Geographic Atrophy Market, By Therapeutic Agents Clinical Phase

6.3.1 Overview and Analysis

6.3.2 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, By Late-Stage (Phase III), 2021- 2031F

6.3.3 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, By Phase II, 2021- 2031F

6.3.4 United Kingdom (UK) Geographic Atrophy Market Revenues & Volume, By Phase I, 2021- 2031F

7.1 United Kingdom (UK) Geographic Atrophy Market Export to Major Countries

7.2 United Kingdom (UK) Geographic Atrophy Market Imports from Major Countries

8.1 Number of clinical trials focused on geographic atrophy in the UK

8.2 Adoption rate of new diagnostic tools for early detection of geographic atrophy

8.3 Patient engagement and education initiatives to increase awareness about the condition

9.1 United Kingdom (UK) Geographic Atrophy Market Opportunity Assessment, By Age Group, 2021 & 2031F

9.2 United Kingdom (UK) Geographic Atrophy Market Opportunity Assessment, By Diagnosis, 2021 & 2031F

9.3 United Kingdom (UK) Geographic Atrophy Market Opportunity Assessment, By Therapeutic Agents Clinical Phase, 2021 & 2031F

10.1 United Kingdom (UK) Geographic Atrophy Market Revenue Share, By Companies, 2024

10.2 United Kingdom (UK) Geographic Atrophy Market Competitive Benchmarking, By Operating and Technical Parameters